Liver Metastases Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Immunotherapy), By Primary Cancer, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
Liver Metastases Treatment Market Growth & Trends
The global liver metastases treatment market is expected to reach USD 2.66 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.3% from 2024 to 2030. Rising prevalence of target disease, advanced stage diagnosis for cancer in developing countries, and increasing number of products approvals is expected to drive the industry growth.
Colorectal cancer, breast cancer, and lung cancer are some of the key types that metastasize to the liver. The incidence of colorectal cancer is expected to increase from 1.88 million in 2020 to 2.45 million in 2030. Whereas the incidence of breast cancer is expected to increase from 2.26 million in 2020 to 2.74 million in 2030. The rising incidence of these primary indications is expected to drive space growth.
Majority of the cancer cases in low and middle-income countries are diagnosed at advanced stages where the availability of therapeutic options is low. The lack of availability of early diagnostics methods combined with uncertain reimbursement scenario for diagnostics are major reasons for delayed diagnosis. The advanced/metastatic stage of diagnosis provide lucrative growth opportunities in this space.
On the other hand, if cancers are diagnosed at advanced stages particularly in developing nations and LMICS, the treatment rate at such advanced stages is significantly less, due to unavailability of products and proper reimbursement. This factor is expected to restrain space growth.
Liver Metastases Treatment Market Report Highlights
- By treatment type, the targeted therapy segment dominated the market with a share of 56.52% to the presence of approved drugs with a price higher than traditional chemotherapy.
- In 2023, colorectal cancer dominated the liver metastases treatment market with a share of 40.55%. Around 25-30% of all colorectal cancers metastasize to the liver. The availability of various treatment options for CCLM further contributed to the segments’ dominance.
- Based on distribution channel, the market was dominated by the hospital pharmacies segment with a share of 60.07% in 2023. The high rate of hospitalization for the treatment of liver metastases is one of the major factors for the dominance of this segment.
- By region, North America has a high revenue share in the global liver metastases treatment market in 2023. However, Asia Pacific is expected to be the fastest growing region during the forecast period.
- Chapter 1 Methodology and Scope
- 1.1 Market Segmentation and Scope
- 1.1.1 Regional scope
- 1.1.2 Estimates and forecast timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased database
- 1.3.2 GVR’s internal database
- 1.3.3 Secondary sources
- 1.3.4 Primary research
- 1.4 Information or Data Analysis
- 1.4.1 Data analysis models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity flow analysis (Model 1)
- 1.6.1.1 Approach 1: Commodity flow approach
- 1.7 Research Assumptions
- 1.8 List of Secondary Sources
- 1.9 List of Abbreviations
- 1.10 Objectives
- 1.10.1 Objective 1
- 1.10.2 Objective 2
- 1.10.3 Objective 3
- 1.10.4 Objective 4
- Chapter 2 Executive Summary
- 2.1 Market Snapshot
- 2.2 Segment Snapshot
- 2.3 Competitive Landscape Snapshot
- Chapter 3 Liver Metastases treatment Market Variables, Trends, and Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent market outlook
- 3.1.1.1 Liver cancer treatment market
- 3.2 Penetration and Growth Prospect Mapping for Treatment Type, 2023
- 3.3 Market Dynamics
- 3.3.1 Market driver analysis
- 3.3.1.1 Approval of targeted therapy for the treatment of liver metastases
- 3.3.2 Market restraint analysis
- 3.3.2.1 Technological advancements for early diagnosis of cancer
- 3.4 Market Analysis Tools
- 3.4.1 Industry analysis: porter’s
- 3.4.1.1 Threat of new entrants
- 3.4.1.2 Bargaining power of buyers
- 3.4.1.3 Competitive rivalry
- 3.4.1.4 Threat of substitutes
- 3.4.1.5 Bargaining power of suppliers
- 3.4.2 Industry analysis: PESTEL
- 3.4.2.1 Political & Legal
- 3.4.2.2 Economical
- 3.4.2.3 Technological
- Chapter 4 Liver Metastases treatment Market: Segment Analysis, by Treatment Type, 2018 - 2030 (USD Million)
- 4.1 Liver Metastases treatment Market: Treatment Type Movement Analysis
- 4.1.1 Chemotherapy
- 4.1.1.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
- 4.1.2 Targeted Therapy
- 4.1.2.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)
- 4.1.3 Immunotherapy
- 4.1.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)
- Chapter 5 Liver Metastases Treatment Market: Segment Analysis, by Primary Cancer, 2018 - 2030 (USD Million)
- 5.1 Liver Metastases treatment Market: Primary Cancer Movement Analysis
- 5.1.1 Colorectal cancer
- 5.1.1.1 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD million)
- 5.1.2 Breast Cancer
- 5.1.2.1 Breast cancer market estimates and forecast, 2018 - 2030 (USD million)
- Chapter 6 Liver Metastases treatment Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
- 6.1 Liver Metastases treatment Market: Distribution Channel Movement Analysis
- 6.1.1 Hospital Pharmacies
- 6.1.1.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
- 6.1.2 Specialty pharmacies
- 6.1.2.1 Specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)
- Chapter 7 Liver Metastases treatment Market: Regional Estimates and Trend Analysis, by Type, Product, & Application
- 7.1 North America
- 7.1.1 SWOT analysis
- 7.1.1.1 North america liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.1.2 U.S.
- 7.1.2.1 Key country dynamics
- 7.1.2.2 Target disease prevalence
- 7.1.2.3 Competitive scenario
- 7.1.2.4 Regulatory framework
- 7.1.2.5 Reimbursement scenario
- 7.1.2.6 U.S. Liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.1.3 Canada
- 7.1.3.1 Key country dynamics
- 7.1.3.2 Target disease prevalence
- 7.1.3.3 Competitive scenario
- 7.1.3.4 Regulatory framework
- 7.1.3.5 Reimbursement scenario
- 7.1.3.6 Canada liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.2 Europe
- 7.2.1 SWOT analysis:
- 7.2.1.1 Europe liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.2.2 Germany
- 7.2.2.1 Key country dynamics
- 7.2.2.2 Target disease prevalence
- 7.2.2.3 Competitive scenario
- 7.2.2.4 Regulatory framework
- 7.2.2.5 Reimbursement scenario
- 7.2.2.6 Germany Liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.2.3 UK
- 7.2.3.1 Key country dynamics
- 7.2.3.2 Target disease prevalence
- 7.2.3.3 Competitive scenario
- 7.2.3.4 Regulatory Framework
- 7.2.3.5 Reimbursement Scenario
- 7.2.3.6 UK liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.2.4 France
- 7.2.4.1 Key country dynamics
- 7.2.4.2 Target disease prevalence
- 7.2.4.3 Competitive scenario
- 7.2.4.4 Regulatory framework
- 7.2.4.5 Reimbursement scenario
- 7.2.4.6 France liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.2.5 Italy
- 7.2.5.1 Key country dynamics
- 7.2.5.2 Target disease prevalence
- 7.2.5.3 Competitive scenario
- 7.2.5.4 Regulatory framework
- 7.2.5.5 Reimbursement scenario
- 7.2.5.6 Italy liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.2.6 Spain
- 7.2.6.1 Key country dynamics
- 7.2.6.2 Target disease prevalence
- 7.2.6.3 Competitive scenario
- 7.2.6.4 Regulatory framework
- 7.2.6.5 Reimbursement scenario
- 7.2.6.6 Spain liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.2.7 Denmark
- 7.2.7.1 Key country dynamics
- 7.2.7.2 Target disease prevalence
- 7.2.7.3 Competitive scenario
- 7.2.7.4 Regulatory framework
- 7.2.7.5 Reimbursement scenario
- 7.2.7.6 Denmark liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.2.8 Sweden
- 7.2.8.1 Key country dynamics
- 7.2.8.2 Target disease prevalence
- 7.2.8.3 Competitive scenario
- 7.2.8.4 Regulatory framework
- 7.2.8.5 Reimbursement scenario
- 7.2.8.6 Sweden liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.2.9 Norway
- 7.2.9.1 Key country dynamics
- 7.2.9.2 Target disease prevalence
- 7.2.9.3 Competitive scenario
- 7.2.9.4 Regulatory framework
- 7.2.9.5 Reimbursement scenario
- 7.2.9.6 Norway liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.3 Asia Pacific
- 7.3.1 SWOT analysis:
- 7.3.1.1 Asia Pacific liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.3.2 Japan
- 7.3.2.1 Key country dynamics
- 7.3.2.2 Target disease prevalence
- 7.3.2.3 Competitive scenario
- 7.3.2.4 Regulatory framework
- 7.3.2.5 Reimbursement scenario
- 7.3.2.6 Japan liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.3.3 China
- 7.3.3.1 Key country dynamics
- 7.3.3.2 Target disease prevalence
- 7.3.3.3 Competitive scenario
- 7.3.3.4 Regulatory framework
- 7.3.3.5 Reimbursement scenario
- 7.3.3.6 China liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.3.4 India
- 7.3.4.1 Key country dynamics
- 7.3.4.2 Target disease prevalence
- 7.3.4.3 Competitive scenario
- 7.3.4.4 Regulatory framework
- 7.3.4.5 Reimbursement scenario
- 7.3.4.6 India liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.3.5 Australia
- 7.3.5.1 Key country dynamics
- 7.3.5.2 Target disease prevalence
- 7.3.5.3 Competitive scenario
- 7.3.5.4 Regulatory framework & reimbursement scenario
- 7.3.5.5 Australia liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.3.6 Thailand
- 7.3.6.1 Key country dynamics
- 7.3.6.2 Target disease prevalence
- 7.3.6.3 Competitive scenario
- 7.3.6.4 Regulatory framework & reimbursement scenario
- 7.3.6.5 Thailand liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.3.7 South Korea
- 7.3.7.1 Key country dynamics
- 7.3.7.2 Target disease prevalence
- 7.3.7.3 Competitive scenario
- 7.3.7.4 Regulatory framework & reimbursement scenario
- 7.3.7.5 South Korea liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.4 Latin America
- 7.4.1 SWOT analysis:
- 7.4.1.1 Latin America liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.4.2 Brazil
- 7.4.2.1 Key country dynamics
- 7.4.2.2 Target disease prevalence
- 7.4.2.3 Competitive scenario
- 7.4.2.4 Regulatory framework
- 7.4.2.5 Reimbursement scenario
- 7.4.2.6 Brazil liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.4.3 Mexico
- 7.4.3.1 Key country dynamics
- 7.4.3.2 Target disease prevalence
- 7.4.3.3 Competitive scenario
- 7.4.3.4 Regulatory framework
- 7.4.3.5 Reimbursement scenario
- 7.4.3.6 Mexico liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.4.4 Argentina
- 7.4.4.1 Key country dynamics
- 7.4.4.2 Target disease prevalence
- 7.4.4.3 Competitive scenario
- 7.4.4.4 Regulatory framework
- 7.4.4.5 Reimbursement scenario
- 7.4.4.6 Argentina liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.5 Middle East & Africa (MEA)
- 7.5.1 SWOT analysis:
- 7.5.1.1 Middle East & Africa liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.5.2 South Africa
- 7.5.2.1 Key Country dynamics
- 7.5.2.2 Target disease prevalence
- 7.5.2.3 Competitive scenario
- 7.5.2.4 Regulatory framework
- 7.5.2.5 Reimbursement scenario
- 7.5.2.6 South Africa liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.5.3 Saudi Arabia
- 7.5.3.1 Key country dynamics
- 7.5.3.2 Target disease prevalence
- 7.5.3.3 Competitive scenario
- 7.5.3.4 Regulatory framework
- 7.5.3.5 Reimbursement scenario
- 7.5.3.6 Saudi Arabia liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.5.4 UAE
- 7.5.4.1 Key country dynamics
- 7.5.4.2 Target disease prevalence
- 7.5.4.3 Competitive scenario
- 7.5.4.4 Regulatory framework
- 7.5.4.5 Reimbursement scenario
- 7.5.4.6 UAE liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.5.5 Kuwait
- 7.5.5.1 Key country dynamics
- 7.5.5.2 Target disease prevalence
- 7.5.5.3 Competitive scenario
- 7.5.5.4 Regulatory framework
- 7.5.5.5 Reimbursement Scenario
- 7.5.5.6 Kuwait liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- 7.5.5.7 Rest of MEA liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
- Chapter 8 Competitive Landscape
- 8.1 Recent Developments & Impact Analysis, by Key Market Participants
- 8.1.1 New product launch
- 8.1.2 Merger and acquisition
- 8.1.3 Licensing agreements
- 8.1.4 Conferences and campaigns
- 8.2 Company Categorization
- 8.2.1 Innovators
- 8.2.2 Market leaders
- 8.3 Vendor Landscape
- 8.3.1 List of key distributors and channel partners
- 8.3.2 Key customers
- 8.4 Public Companies
- 8.4.1 Key company market share analysis, 2023
- 8.4.2 Company market position analysis
- 8.4.3 Heat map analysis
- 8.4.4 Competitive dashboard analysis
- 8.4.4.1 Market differentiators
- 8.5 Private Companies
- 8.5.1 List of key emerging companies
- 8.5.2 Regional network map
- 8.6 Company Profiles
- 8.6.1. F. Hoffmann-La Roche Ltd.
- 8.6.1.1 Company overview
- 8.6.1.2 Financial performance
- 8.6.1.3 Product benchmarking
- 8.6.1.4 Strategic initiatives
- 8.6.2 AstraZeneca
- 8.6.2.1 Company overview
- 8.6.2.2 Financial performance
- 8.6.2.3 Product benchmarking
- 8.6.2.4 Strategic initiatives
- 8.6.3 Bayer AG
- 8.6.3.1 Company overview
- 8.6.3.2 Financial performance
- 8.6.3.3 Product benchmarking
- 8.6.3.4 Strategic initiatives
- 8.6.4 Eli Lilly and Company
- 8.6.4.1 Company overview
- 8.6.4.2 Financial performance
- 8.6.4.3 Product benchmarking
- 8.6.4.4 Strategic initiatives
- 8.6.5 Ono Pharmaceutical
- 8.6.5.1 Company overview
- 8.6.5.2 Financial performance
- 8.6.5.3 Product benchmarking
- 8.6.5.4 Strategic initiatives
- 8.6.6 Pfizer, Inc.
- 8.6.6.1 Company overview
- 8.6.6.2 Financial performance
- 8.6.6.3 Product benchmarking
- 8.6.6.4 Strategic initiatives
- 8.6.7 Bristol-Myers Squibb Company
- 8.6.7.1 Company overview
- 8.6.7.2 Financial performance
- 8.6.7.3 Product benchmarking
- 8.6.7.4 Strategic initiatives
- 8.6.8 Cadila Pharmaceuticals Ltd.
- 8.6.8.1 Company overview
- 8.6.8.2 Financial performance
- 8.6.8.3 Product benchmarking
- 8.6.8.4 Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook